Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
暂无分享,去创建一个
John B Buse | B. Zinman | S. Pocock | N. Poulter | R. Bergenstal | S. Nissen | J. Buse | G. Daniels | M. Nauck | W. Steinberg | S. Marso | J. Mann | Johannes F E Mann | Neil R Poulter | Bernard Zinman | Steven E Nissen | Michael A Nauck | Stuart Pocock | Richard M Bergenstal | Steven P Marso | L. Ravn | M. Stockner | Gilbert H Daniels | Kirstine Brown-Frandsen | Peter Kristensen | Lasse S Ravn | William M Steinberg | Mette Stockner | P. Kristensen | K. Brown-Frandsen
[1] M. Pencina,et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. , 2015, The New England journal of medicine.
[2] K. Almholt,et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. , 2010, Endocrinology.
[3] Deepak L. Bhatt,et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. , 2013, The New England journal of medicine.
[4] M. Nauck,et al. Incretin therapies: highlighting common features and differences in the modes of action of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors , 2016, Diabetes, obesity & metabolism.
[5] D. Drucker,et al. Cardiovascular actions of incretin-based therapies. , 2014, Circulation research.
[6] R. DeFronzo,et al. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. , 2015, JAMA.
[7] Craig Wilson,et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. , 2013, The New England journal of medicine.
[8] D G Altman,et al. Calculating the number needed to treat for trials where the outcome is time to an event , 1999, BMJ.
[9] M. Diamant,et al. The gut–renal axis: do incretin-based agents confer renoprotection in diabetes? , 2014, Nature Reviews Nephrology.
[10] 岩井 孝志. Glucagon-like peptideの精神・神経障害に対する作用 , 2010 .
[11] M. Pencina,et al. Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial. , 2016, JAMA cardiology.
[12] S. Solomon,et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. , 2015, The New England journal of medicine.
[13] T. Vilsbøll,et al. Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes – focus on pancreatitis and pancreas cancer , 2015, Expert opinion on drug safety.
[14] Tetsuhiro Tanaka,et al. The potential for renoprotection with incretin-based drugs. , 2014, Kidney international.
[15] B. Zinman,et al. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. , 2013, American heart journal.
[16] Salim Yusuf,et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. , 2012, The New England journal of medicine.
[17] M. Fischereder,et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2016, The New England journal of medicine.
[18] W. Steinberg,et al. Is There a Link Between Liraglutide and Pancreatitis? A Post Hoc Review of Pooled and Patient-Level Data From Completed Liraglutide Type 2 Diabetes Clinical Trials , 2015, Diabetes Care.
[19] M. Hanefeld,et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial , 2009, The Lancet.
[20] Erland Erdmann,et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.
[21] H. Randeva,et al. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis , 2013, BMJ Open.
[22] C. Tseng,et al. An Updated Review on Cancer Risk Associated with Incretin Mimetics and Enhancers , 2015, Journal of environmental science and health. Part C, Environmental carcinogenesis & ecotoxicology reviews.
[23] Yue-Yang Zhao,et al. Liraglutide for the Treatment of Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Placebo-Controlled Trials , 2014, Advances in Therapy.
[24] R. Califf,et al. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes , 2014, The Lancet.